| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 5.4 | $5k-$25k | 0.00 |
Summary
A vulnerability classified as critical has been found in IBM Verify Gateway 1.0.0/1.0.1. Affected by this issue is some unknown functionality. The manipulation leads to hard-coded credentials. This vulnerability is referenced as CVE-2020-4385. Remote exploitation of the attack is possible. No exploit is available.
Details
A vulnerability was found in IBM Verify Gateway 1.0.0/1.0.1. It has been rated as critical. This issue affects some unknown processing. The manipulation with an unknown input leads to a hard-coded credentials vulnerability. Using CWE to declare the problem leads to CWE-798. The product contains hard-coded credentials, such as a password or cryptographic key, which it uses for its own inbound authentication, outbound communication to external components, or encryption of internal data. Impacted is confidentiality. The summary by CVE is:
IBM Verify Gateway (IVG) 1.0.0 and 1.0.1 contains hard-coded credentials, such as a password or cryptographic key, which it uses for its own inbound authentication, outbound communication to external components, or encryption of internal data. IBM X-Force ID: 179266.
The weakness was published 07/22/2020 (Website). The advisory is shared at ibm.com. The identification of this vulnerability is CVE-2020-4385 since 12/30/2019. The exploitation is known to be difficult. The attack may be initiated remotely. No form of authentication is needed for a successful exploitation. Neither technical details nor an exploit are publicly available. The price for an exploit might be around USD $5k-$25k at the moment (estimation calculated on 07/23/2020). It is expected to see the exploit prices for this product increasing in the near future.MITRE ATT&CK project uses the attack technique T1110.001 for this issue.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
Similar entries are available at VDB-158888, VDB-158887, VDB-158886 and VDB-158884. If you want to get the best quality for vulnerability data then you always have to consider VulDB.
Product
Vendor
Name
Version
License
Website
- Vendor: https://www.ibm.com/
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 5.4VulDB Meta Temp Score: 5.4
VulDB Base Score: 4.0
VulDB Temp Score: 4.0
VulDB Vector: 🔍
VulDB Reliability: 🔍
NVD Base Score: 6.8
NVD Vector: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
Exploiting
Class: Hard-coded credentialsCWE: CWE-798 / CWE-259 / CWE-255
CAPEC: 🔍
ATT&CK: 🔍
Physical: No
Local: No
Remote: Yes
Availability: 🔍
Status: Not defined
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔍
Timeline
12/30/2019 🔍07/22/2020 🔍
07/23/2020 🔍
11/05/2020 🔍
Sources
Vendor: ibm.comAdvisory: ibm.com
Status: Not defined
Confirmation: 🔍
CVE: CVE-2020-4385 (🔍)
GCVE (CVE): GCVE-0-2020-4385
GCVE (VulDB): GCVE-100-158885
X-Force: 179266
See also: 🔍
Entry
Created: 07/23/2020 09:21Updated: 11/05/2020 11:20
Changes: 07/23/2020 09:21 (39), 07/23/2020 09:26 (11), 11/05/2020 11:11 (2), 11/05/2020 11:20 (1)
Complete: 🔍
Cache ID: 216::103
If you want to get the best quality for vulnerability data then you always have to consider VulDB.
No comments yet. Languages: en.
Please log in to comment.